Akeso/Summit’s Bispecific Ivonescimab Bests Keytruda In 1L NSCLC

China-Only Study But Big Implications?

 
• By Dexter Jie Yan
  
Cancer survival
Ivonescimab comes out strong in China head-to-head trial with Keytruda in first-line NSCLC • Source: Shutterstock

More from China

More from Focus On Asia